Literature DB >> 24416569

Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature.

Patrizia Ciammella1, Maria Galeandro1, Nunziata D'Abbiero1, Tamara Palmieri1, Elisa Donini1, Cinzia Iotti1.   

Abstract

INTRODUCTION: Prostate embryonal rhabdomyosarcoma (ERMS) is a common tumour in infants and children, with a median occurrence age of 5 years, but it is rare in adults. It is characterized by a high degree of malignancy, both local rapid growth with formation of large pelvic masses, often leading to renal failure due to urethral obstruction, and systemic spread, commonly to the lungs, liver and bone. Several therapeutic approaches have been employed in the effort to treat prostate ERMS, but all of them have failed to gain a significant survival benefit in adult patients. CASE REPORT: We report on a case of a stage IV prostate ERMS, approached with combined-modality treatment, with the administration of 5 courses of doxorubicin, ifosfamide and 2-mercaptoethane sulfonate sodium (mesna), and, subsequent radiotherapy to the prostatic bed (60 Gy/30 fxs). The patient remained free of progression of disease for about 1 year to finally experience a systemic relapse with multiple lung metastases and pleural effusion. The patient died for metastatic disease 27 months following the initial diagnosis.
CONCLUSION: While it remains questionable which therapeutic approach for prostate ERMS in adults is the most appropriate, our report demonstrates that a chemo-radiation combined treatment can control the prostate disease, reducing the symptoms and improving the quality of life of these patients, for the most part destined to die for systemic progression of disease.

Entities:  

Keywords:  Adults; Embrional; Prostate cancer; Radiation therapy; Rhabdomyosarcoma

Year:  2013        PMID: 24416569      PMCID: PMC3863144          DOI: 10.1016/j.rpor.2013.03.007

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  14 in total

Review 1.  Treatment modalities of bladder/prostate rhabdomyosarcoma: a review.

Authors:  R Ashlock; P A S Johnstone
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

2.  UROGENITAL RHABDOMYOSARCOMA: HISTOGENESIS AND CLASSIFICATION.

Authors:  J G BATSAKIS
Journal:  J Urol       Date:  1963-08       Impact factor: 7.450

3.  Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy.

Authors:  Yuki Kojima; Kenji Hashimoto; Masashi Ando; Kan Yonemori; Akihiro Hirakawa; Makoto Kodaira; Mayu Yunokawa; Chikako Shimizu; Kenji Tamura; Noriyuki Katsumata; Ako Hosono; Atsushi Makimoto; Yasuhiro Fujiwara
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-23       Impact factor: 4.553

4.  Adult urological sarcoma.

Authors:  P Russo; M S Brady; K Conlon; S I Hajdu; W R Fair; H W Herr; M F Brennan
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

5.  Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma.

Authors:  N F Esnaola; B P Rubin; E H Baldini; N Vasudevan; G D Demetri; C D Fletcher; S Singer
Journal:  Ann Surg       Date:  2001-08       Impact factor: 12.969

6.  Adult rhabdomyosarcoma: outcome following multimodality treatment.

Authors:  Darren J Little; Matthew T Ballo; Gunar K Zagars; Peter W T Pisters; Shreyaskumar R Patel; Adel K El-Naggar; Adam S Garden; Robert S Benjamin
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

7.  Urologic sarcoma in adults. Memorial Sloan-Kettering Cancer Center experience based on a prospective database between 1982 and 1989.

Authors:  P Russo
Journal:  Urol Clin North Am       Date:  1991-08       Impact factor: 2.241

Review 8.  Prostatic embryonal rhabdomyosarcoma in adults. A clinicopathologic review.

Authors:  P M Waring; R C Newland
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

9.  Rhabdomyosarcoma of the head and neck in children.

Authors:  J Hicks; C Flaitz
Journal:  Oral Oncol       Date:  2002-07       Impact factor: 5.337

10.  Prognostic factors and clinical outcomes of urological soft tissue sarcomas.

Authors:  Geonseok Lee; Seo Yeon Lee; Seongil Seo; Seongsoo Jeon; Hyunmoo Lee; Hanyong Choi; Byong Chang Jeong
Journal:  Korean J Urol       Date:  2011-10-19
View more
  6 in total

1.  Tailor-made treatment combined with proton beam therapy for children with genitourinary/pelvic rhabdomyosarcoma.

Authors:  Hiroko Fukushima; Takashi Fukushima; Aiko Sakai; Ryoko Suzuki; Chie Kobayashi; Yoshiko Oshiro; Masashi Mizumoto; Noriko Hoshino; Chikashi Gotoh; Yasuhisa Urita; Hiroaki Komuro; Michio Kaneko; Noritoshi Sekido; Kouji Masumoto; Hideyuki Sakurai; Ryo Sumazaki
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-09

Review 2.  Spindle cell embryonal rhabdomyosarcoma of the prostate in an adult patient - case report and review of clinicopathological features.

Authors:  Hans-Ulrich Schildhaus; Suvi Lokka; Werner Fenner; Jens Küster; Ingrid Kühnle; Ernst Heinmöller
Journal:  Diagn Pathol       Date:  2016-06-29       Impact factor: 2.644

3.  A Rare Case of Adult Rhabdomyosarcoma.

Authors:  Benjamin Sparreboom; Brendan Litton; Julian Yaxley
Journal:  Pol J Radiol       Date:  2017-07-22

4.  Rhabdomyosarcoma of the prostate with bladder and urethral infiltration: A case report.

Authors:  Sahat Matondang; Benedicta M Suwita; Taufik Budianto; Yayi Dwina
Journal:  Urol Case Rep       Date:  2020-04-10

5.  Epidemiology and survival outcome of adult kidney, bladder, and prostate rhabdomyosarcoma: A SEER database analysis.

Authors:  Sagar R Patel; Caitlin P Hensel; Jiaxian He; Nicolas E Alcalá; James T Kearns; Kris E Gaston; Peter E Clark; Stephen B Riggs
Journal:  Rare Tumors       Date:  2020-12-04

6.  Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas.

Authors:  Jonathan D Tward; Matthew M Poppe; Ying J Hitchcock; Brock O'Neil; Daniel J Albertson; Dennis C Shrieve
Journal:  Cancer Med       Date:  2018-11-19       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.